1 / 9

Injectable Cell Therapy for Degenerative Disc Disease

Injectable Cell Therapy for Degenerative Disc Disease. Richard Melpignano. Degenerative Disc Disease. The natural degeneration of the Intervertebral Discs (IVD) and nucleus pulposus (NP), which is the spinal cord ’ s jelly-like shock absorber

ksena
Télécharger la présentation

Injectable Cell Therapy for Degenerative Disc Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Injectable Cell Therapy for Degenerative Disc Disease Richard Melpignano

  2. Degenerative Disc Disease • The natural degeneration of the Intervertebral Discs (IVD) and nucleus pulposus (NP), which is the spinal cord’s jelly-like shock absorber • Most commonly affects lumbar & cervical regions in older patients • Can lead to Osteoarthritis (the breakdown of protective cartilage), herniated discs, and spinal stenosis

  3. Treatment • Injection of NP cells inside a liquid suspension directly into IVD • Purpose is to promote tissue regeneration • Current liquid delivery medium is ineffective; can only hold cells in place for 3-4 days

  4. Advancements • In July 2013, Researchers from Duke University created a new biomaterial suspension for NP injection • Made up of the chemically modified protein laminin-111 and two polyethylene glycol hydrogels • Injected as a liquid and quickly forms into a gel • Gel mimics laminin (protein native to NP). This ensures persistence and biosynthesis of the injected NP cells

  5. Procedure • All three substances are injected directly into affected IVD • Takes about a minute to inject, 5 minutes to begin to solidify, and 20 minutes to completely set

  6. Results • Luciferase biomarkers used to track migration of injected cells • Two weeks after injection, significantly more cells remained in place when delivered within the biomaterial suspension in comparison to the traditional liquid suspension

  7. Future • Still much work to be done; not yet practical for use on humans • Injection sites are still not large enough to deliver NP cells to larger IVD sites that are present in humans (in comparison to mice used in tests) • Additional studies that evaluate disc height or matrix hydration following cell delivery would further optimize this treatment

  8. Works Cited • Aubrey T. Francisco, Robert J. Mancino, Robby D. Bowles, Jonathan M. Brunger, David M. Tainter, Yi-Te Chen, William J. Richardson, Farshid Guilak, Lori A. Setton, Injectable laminin-functionalized hydrogel for nucleus pulposus regeneration, Biomaterials, Volume 34, Issue 30, October 2013, Pages 7381-7388, ISSN 0142-9612, http://dx.doi.org/10.1016/j.biomaterials.2013.06.038. • "Cell Therapies May Stop or Reverse Pain and Disability of Degenerative Disc Disease." Cell Therapies May Stop or Reverse Pain and Disability of Degenerative Disc Disease. N.p., n.d. Web. 17 Nov. 2013. <http://www.news-medical.net/news/20130717/Cell-therapies-may-stop-or-reverse-pain-and-disability-of-degenerative-disc-disease.aspx> • "Degenerative Disc Disease-Topic Overview." WebMD. WebMD, 07 Jan. 0000. Web. 17 Nov. 2013. <http://www.webmd.com/back-pain/tc/degenerative-disc-disease-topic-overview>. • Duke University. "Bioengineers develop new approach to regenerate back discs." ScienceDaily, 16 Jul. 2013. Web. 17 Nov. 2013.

More Related